Molecular Partners AG Board of Directors

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Dr. Patrick Amstutz Ph.D.

Dr. Patrick Amstutz Ph.D.

Co-Founder, CEO, Member of Management Board & Director

Mr. Michael Pitzner

Mr. Michael Pitzner

General Counsel, Compliance Officer, Senior VP Legal & Business Development

Mr. Daniel Steiner Ph.D.

Mr. Daniel Steiner Ph.D.

Senior Vice President of Research & Technology

Mr. Seth D. Lewis

Mr. Seth D. Lewis

Senior Vice President of Investor Relations, Communications & Strategy

Mr. Alexander Zurcher

Mr. Alexander Zurcher

COO & Member of Management Board

Ms. Anne Goubier D.V.M., Ph.D.

Ms. Anne Goubier D.V.M., Ph.D.

Senior Vice President of Research & Early Development

Ms. Renate Gloggner

Ms. Renate Gloggner

Executive VP of People & Community and Member of Management Board

Mr. Robert Hendriks

Mr. Robert Hendriks

Senior VP of Finance

Dr. Michael Tobias Stumpp Ph.D.

Dr. Michael Tobias Stumpp Ph.D.

Co-Founder, Executive VP of Projects & Member of Management Board

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.